[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiometabolic-risk-factors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiometabolic-risk-factors":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,47,59,91,121,157,191,216,260,287,315,346,372,390,423,448,472,502],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100053215","a-natural-history-of-cardiometabolic-disease-among-us-bhutanese-developing-the-cross-sectional-bhutanese-community-of-central-ohio-health-study-to-understand-acculturation-as-synergizing-socioenvironmental-and-biobehavioral-risk-factors-propagating--100053215",false,"NCT06991751","A Natural History of Cardiometabolic Disease Among US Bhutanese: Developing the Cross-Sectional Bhutanese Community of Central Ohio Health Study to Understand Acculturation as Synergizing Socioenvironmental and Biobehavioral Risk Factors Propagating ...","A Natural History of Cardiometabolic Disease Among US Bhutanese: Developing the Bhutanese Community of Central Ohio Health Study to Identify Synergizing Socioenvironmental and Biobehavioral Risk Factors Propagating Health Disparities From a Cross-Sectional Study","* INCLUSION CRITERIA:\n\nTo participate in this study all of the following criteria must be met:\n\n* Adults (aged 18 years and older) living in the United States\n* Identify as Bhutanese, which will be defined as those individuals that resided or had\u002Fhave their closest relatives residing in the Kingdom of Bhutan\n* Bhutanese identity will also include those that self-identify as Bhutanese-Nepali or Bhutanese American\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Any South Asian participants that do not identify as Bhutanese.\n* Pregnant at time of study or screening","ALL","18 Years","100 Years",{"count":20,"type":21},50,"ESTIMATED","OBSERVATIONAL","Background:\n\nAs of 2021, almost 45 million people in the United States were foreign-born immigrants. South Asians, including people from Bhutan, are the fastest-growing immigrant subgroup in the US. Their income and education levels are higher than the US average. Yet they have worse physical and mental health outcomes than their White US-born counterparts. These risks include type 2 diabetes and obesity.\n\nObjective:\n\nThis natural history study will explore how life experiences and environmental factors affect heart health and metabolism among Bhutanese people living in the US.\n\nEligibility:\n\nAdults aged 18 years or older who identify as Bhutanese and live in the US.\n\nDesign:\n\nParticipants will be recruited and screened by the Bhutanese Community of Central Ohio (BCCO). They will have 1 visit to the BCCO s Arogya Clinic in Reynoldsburg. The visit will last 2 hours.\n\nParticipants will take a survey; they may use either English or Nepali. They will answer questions about their background; their experiences living in the US; and how their customs and habits might have changed. They will also be asked about their experiences with discrimination; their mental health and well-being; their community; quality of life; and overall physical health. The survey will take 60 minutes.\n\nParticipants will also speak with a researcher. They will be asked how they feel about providing biological samples; these may include saliva, blood, and urine. Their answers will be audio recorded.",[25,26],"Cardiometabolic Risk Factors","Mental Health",[28,29,30,31,32,33],"Bhutanese","South Asian","Community engaged","Biospecimen perceptions","Epidemiology","Syndemic","NOT_YET_RECRUITING","2026-07-10",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":21},"2026-07-16",{"date":42,"type":21},"2026-08-31",{"name":44,"class":45},"National Institute of Environmental Health Sciences (NIEHS)","NIH",1,{"id":48,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":50,"keywords":51,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":58,"locationsCount":46},"100592309",{"count":20,"type":21},[25,26],[28,29,30,31,32,33],"2026-07-01",{"date":54,"type":38},"2026-07-02",{"date":56,"type":21},"2026-07-07",{"date":42,"type":21},{"name":44,"class":45},{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":16,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":71,"conditions":72,"keywords":77,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":46},"100645093","the-muscle-monitor-early-skeletal-muscle-indicators-of-insulin-resistance-and-cardiometabolic-risk-100645093","NCT07678736","The Muscle Monitor: Early Skeletal Muscle Indicators of Insulin Resistance and Cardiometabolic Risk","The Muscle Phenotype and Cardiometabolic Health Monitoring Project","MUSCLE MONITOR","Inclusion Criteria:\n\n* Sex: Males and females\n* Age: 20-30 years\n* BMI \\\u003C35\n* Healthy (no diagnosed chronic disease)\n\nExclusion Criteria:\n\n* Chronic disease deemed to affect study outcomes\n* Disease that increase haemorrhage risk\n* Daily intake of medication that could confound study outcomes\n* Regular smokers\n* Active pregnancy\n* Immobilization (inactivity due to injury or illness, e.g. cast or brace) for more than a week in the month prior to the study or for more than 4 weeks in the past 6 months prior to the study\n* Very high structured physical exercise level (\\>10 h\u002Fweek).\n* Participants not willing to adhere to standardized meal prescriptions included in the study protocols will also be excluded (due to e.g. allergies or specific dietary preferences)","20 Years","30 Years",{"count":70,"type":21},250,"Insulin resistance is an early etiological factor in the development of type-2 diabetes (T2D), which constitutes a large societal health burden with an expected additional rise in the years to come.\n\nSkeletal muscle is the body's largest lean tissue mass and the major site of glucose disposal in response to insulin stimulation. Prior studies have suggested that a fast skeletal muscle phenotype, including a predominant fast muscle fiber composition, reduced capillary density, low fat oxidation and muscle oxidative capacity may be implicated in insulin resistance and TD2 development. However, key questions pertain in relation to the cause and effect of these relationships as well as the interaction with potential confounders and effect-modifiers including life-style factors (e.g. diet and physical activity levels) and general participant characteristics (e.g. body composition and training status).\n\nIn the present project, we therefore aim to derive muscle fiber type and extensively map the proteomic signature of the early stages of insulin resistance in a large cross-sectional study using a young and apparently healthy cohort prior to T2D development, including a thorough participant characterization. We will recruit \\~250 participants (men and women) in the age of 20-30 years and conduct extensive phenotyping and tissue sampling across one laboratory-based test day and a scan visit, as well as measurements of physical activity level and glucose handling in free-living conditions with wearable sensors.\n\nThe study has a longitudinal aspect as participants will be re-invited at 5-year intervals for up to 20 years to delineate the trajectory of metabolic health in relation to muscle phenotype measures.\n\nThe results of the project are expected to lead to significant advancements in our understanding of the importance of muscle phenotype for early-stage insulin resistance and metabolic health trajectories. Such understanding has potentially important clinical implications, as it can open new avenues for targeted interventions and individualized early preventive strategies to counter or delay the progression of insulin resistance and associated metabolic and cardiovascular disorders.",[73,74,25,75,76],"Insulin Resistance","Insulin Resistance and Type 2 Diabetes","Physical Activity","Muscle Fiber Type",[78,79,80],"Insulin sensitivity","Skeletal muscle","Physical activity","RECRUITING","2026-06-24",{"date":52,"type":38},{"date":85,"type":38},"2025-05-19",{"date":87,"type":21},"2046-12-31",{"name":89,"class":90},"University Ghent","OTHER",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":99,"sex":16,"minAge":67,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":103,"phases":104,"briefSummary":106,"conditions":107,"keywords":110,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":46},"100643424","health-effects-of-ultra-processed-food-intake-100643424","NCT07634159","Health Effects of Ultra-processed Food Intake","Health Effects of Ultra-processed Food Intake: a Randomized Crossover Feeding Study","UPFront","Inclusion Criteria:\n\n* Age 20-60 years\n* Weight stable (less than 5% weight change in the past 3 months)\n* No plans to change weight\n* Willing to eat the study diet and a mixed diet\n* Has provided informed consent to participate in the study\n\nExclusion Criteria:\n\n* Allergy or intolerance to foods included in the study. Participants with lactose intolerance treated with lactase may participate if they take enzymes.\n* BMI \\\u003C18.5 or \\>35 kg\u002Fm²\n* Use of medications known to significantly affect appetite (e.g., oral corticosteroids, antipsychotic medications, or GLP-1 receptor agonists)\n* Use of lipid-lowering medications (e.g., statins or PCSK9 inhibitors)\n* Diagnosed diabetes or capillary blood glucose at or above 12.2 mmol\u002FL\n* Disease associated with malabsorption (e.g., inflammatory bowel disease or celiac disease)\n* Previous bariatric surgery\n* Established cardiovascular disease (heart failure, myocardial infarction, or stroke) or cancer\n* Pregnancy or breastfeeding, or plans to become pregnant or breastfeed during the study",true,"60 Years",{"count":102,"type":21},40,"INTERVENTIONAL",[105],"NA","Ultra-processed food (UPF) intake has been related to negative health effects and incresed energy intake in previous intervention studies. Thus, previous studies have seen weight gain from higher UPF intake which obscures the potentital to see effects on cardiometabolic biomarkers, independent of weight changes. The overall aim of this project is to study the causal effects of a high UPF diet, compared to a nutrient-matched low UPF diet, on appetite and cardiometabolic health in a weight-stable context.",[25,108,109],"Microbiota","Diet Interventions",[111],"Ultra-processed food","2026-06-03",{"date":114,"type":38},"2026-06-08",{"date":116,"type":21},"2026-08",{"date":118,"type":21},"2027-12",{"name":120,"class":90},"Göteborg University",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":99,"sex":128,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":103,"phases":133,"briefSummary":134,"conditions":135,"keywords":140,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":46},"100589347","acute-impact-of-whey-protein-enriched-milk-fat-globule-membrane-supplementation-on-postprandial-markers-of-heart-and-brain-health-100589347","NCT06953232","Acute Impact of Whey Protein-enriched Milk Fat Globule Membrane Supplementation on Postprandial Markers of Heart and Brain Health","Acute Impact of Whey Protein-enriched Milk Fat Globule Membrane Supplementation on Postprandial Markers of Heart and Brain Health in Postmenopausal Women Living With Overweight and at Moderate Risk for Cardiovascular Disease.","Inclusion Criteria:\n\n* Apparently healthy postmenopausal women (not menstruating for 12 or more months)\n* Aged 50 - 75 years\n* BMI: 25 - 40 kg\u002Fm²\n* Moderate CVD risk\n* Recreationally active (\\> 3 x 30 min moderate exercise per week)\n* Understands and is willing and able to comply with all study procedures including eating a high-fat breakfast meal\n* Fluent in written and spoken English\n* Access to, and able to use, the internet\u002Fcomputer\u002Ftablet device\n\nExclusion Criteria:\n\n* Smoking (including vaping)\n* Diagnosed with cardiovascular disease or suffered myocardial infarction \u002Fstroke in the past twelve months\n* Existing or significant past medical history of any medical condition likely to affect the study outcomes e.g., diabetes, digestive, cancer or thyroidal disease, neurological disease (Alzheimer's disease, other form of dementia, mild cognitive impairment), or serious mental illness know to affect cognition (schizophrenia, schizoaffective disorder, bipolar disorder), learning disorders (dyslexia)\n* Early or premature menopause resulting from medical conditions or undergoing surgery\n* Hormone replacement therapy within last 6 months\n* Prescribed medications likely to interfere with study outcomes (including lipid\u002Fcholesterol-lowering medications, including statins; blood thinners, antiplatelets (anticoagulants) such as heparin, etc.; medications for blood pressure; inflammation such as nonsteroidal anti-inflammatory drugs, aspirin, etc.; immune function, or lipid\u002Fcarbohydrate metabolism) or prescribed antibiotics within the last three months\n* Use of antidepressant or anti-anxiety medication if it has changed in the last three months or expected to change within the 3-month study period\n* Taking vitamin, mineral, or fatty acid supplements (e.g., fish oil, calcium) or unwilling stop consuming these for the duration of the study (including sufficient washout period)\n* Working night shifts\n* Inaccessible veins for blood collection via cannulation\n* Unstable weight history (≥3 kg loss or gain in the previous 3 months) or planning or currently on a weight reduction scheme\n* Known allergy or intolerance to study food (including lactose intolerance, dairy, and wheat)\n* Being vegan or any other unusual medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a dietary intervention or metabolic study\n* Excessive alcohol consumption: \\>21 unit\u002Fwk (i.e., more than 10 and a half pints of beer or 21 small glasses of wine)\n* Currently taking part or have participated in another research study in the last two months (e.g., dietary intervention)","FEMALE","50 Years","75 Years",{"count":132,"type":21},16,[105],"In a single-blind, randomised, placebo-controlled crossover manner, this study aims to assess the impact of a high-fat mixed meal containing a whey protein (WP)-enriched milk fat globule membrane (MFGM) powdered ingredient on markers of heart and brain health in the fed state among middle-to-older-aged, postmenopausal women living with overweight and at moderate risk for cardiovascular disease.\n\nParticipants will attend two \\~8 hour study visits, where they will consume a high-fat meal containing a WP-enriched MFGM powdered ingredient or a placebo WP-based powdered ingredient. Each visit will involve anthropometric measurements and periodic assessments of heart health, including blood pressure and blood vessel stiffness measurements, blood sample collections, as well as computer-based tests measuring mood and cognition (brain function) over a 6-hour postprandial period.",[136,137,138,139,25],"Cardiovascular Diseases","Cognition","Overweight or Obesity","Postmenopausal Women",[141,142,143,144,145,146,147],"Milk fat globule membrane","Milk polar lipids","triacylglycerol","postprandial","cholesterol","cardiometabolic disease risk","cognitive function","2026-05-18",{"date":150,"type":38},"2026-05-20",{"date":152,"type":38},"2025-09-30",{"date":154,"type":21},"2026-10",{"name":156,"class":90},"Loughborough University",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":103,"phases":168,"briefSummary":170,"conditions":171,"keywords":175,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":46},"100617716","phase-4-dice-study--diastolic-improvement-with-carvedilol--empagliflozin-in-patients-with-cirrhosis-100617716","NCT07322237","DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis","Empagliflozin + Carvedilol vs. Carvedilol Alone for Patients With Cirrhosis and Left Ventricular Diastolic Dysfunction and Impact on Hepatic Decompensation and Survival: A Double-Blind Placebo-Controlled Randomized Controlled Trial","DICE","Inclusion criteria\n\n* Age range of 18-65 years\n* Cirrhosis as diagnosed by histology or clinical laboratory and USG findings\n* LVDD (with EF\\>50%) on 2D echocardiography with TDI\n* Written informed consent.\n\nExclusion criteria\n\n* Age \\>65 years\n* Serum Creatinine\\>2 mg\u002Fdl\n* History of urinary tract \u002Fgenital infections in last 3 months\n* Patient on treatment with statin (one month before the study)\n* Advanced Cirrhosis (MELD\\>20)\n* Coronary artery disease\n* Sick sinus syndrome\u002F Pacemaker valvular heart disease\n* Cardiac rhythm disorder Peripartum cardiomyopathy\n* Portopulmonary hypertension\u002F hepatopulmonary syndrome\n* Transjugular intrahepatic porto systemic shunt (TIPS) insertion\n* Hepatocellular carcinoma\n* Pregnancy or lactation\n* Patients with HIV or retroviral therapy\n* Anemia Hb \\\u003C 8gm\u002Fdl in females and \\\u003C 9 gm\u002Fdl in males\n* Acute variceal bleeding in last 6months.","65 Years",{"count":167,"type":21},400,[169],"PHASE4","1. This proposed double-blind placebo controlled randomized controlled trial incorporates recent advances in management of heart failure and portal hypertension using the SGLT-2 inhibitor i.e. EMPAGLIFLOZIN. The drug has been found to be useful in large trials on heart failure with preserved ejection fraction in the general population with improvement in MASLD progression, with improvement in body weight and hepatic steatosis but no change in liver fibrosis.\n2. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce the development and progression of heart failure in patients with type 2 diabetes and in those with heart failure and a reduced and preserved ejection fraction. In patients with cirrhosis safety of empagliflozin in a dose of 10 mg has been demonstrated.\n3. Prevention of decompensation related events in cirrhosis is the key endpoint of any liver-directed therapy as the median survival in the compensated state exceeds 10 years but median survival in the decompensated state approximates 1.5 years. Previous data has demonstrated the risk of hepatic decompensation acute kidney injury and poor survival in patients with cirrhosis and heart failure with preserved ejection fraction (HFpEF) i.e. LVDD a large subset of whom meet criteria for CCM.",[172,173,25,174],"Cirrhotic Cardiomyopathy","Empagliflozin","Cirrhosis",[176,177,178,179,180,181],"Empagliflozin in cirrhosis","Carvedilol in Cirrhosis","SGLT-2 inhibitor","Ascites","Diastolic heart failure","heart failure with preserved ejection fraction","2026-05-13",{"date":184,"type":38},"2026-05-14",{"date":186,"type":38},"2026-04-01",{"date":188,"type":21},"2029-06-30",{"name":190,"class":90},"Post Graduate Institute of Medical Education and Research, Chandigarh",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":99,"sex":16,"minAge":17,"maxAge":165,"enrollmentInfo":198,"targetDuration":4,"studyType":103,"phases":200,"briefSummary":201,"conditions":202,"keywords":203,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":215},"100573672","dissecting-the-roles-of-high-quality-diets-and-ultra-processed-foods-on-cardiometabolic-health-100573672","NCT06749327","Dissecting the Roles of High-quality Diets and Ultra Processed Foods on Cardiometabolic Health","Ultra-processed Foods, Diet Quality, and Cardiometabolic Health","Inclusion Criteria:\n\n* Men and women aged between 18 and 65 years in general good health with BMI \\\u003C 35 kg\u002Fm2 who can provide informed consent.\n\nExclusion Criteria:\n\n* Participants will be ineligible to enrol if they have diabetes, CVD, any type of cancer (except for basal cell skin cancer), or a condition (pregnancy, breastfeeding, etc) or dietary restriction(s) that would substantially limit their ability to complete the study.\n\nIndividuals will be screened for their adherence to the Plant based diet Index (PDI ).\n\n1. Individuals with low adherence will enter run-in phase only (6 weeks)\n2. Individuals with high adherence will enter the main intervention (4 months)",{"count":199,"type":21},330,[105],"Controversy remains around the role of ultra-processed food (UPF) consumption and health outcomes. A key question that remains to be answered is: when diet quality is the same, does food processing itself have any independent health effects? The current application aims to isolate the health effects of food processing from those of diet quality through the conduct of a dietary intervention study.",[25],[204,205,206,207],"Plant-based diets","Diet quality","Cardiometabolic risk factors","Ultra-processed foods",{"date":148,"type":38},{"date":210,"type":21},"2026-10-01",{"date":212,"type":21},"2029-06-01",{"name":214,"class":90},"Queen's University, Belfast",2,{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":99,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":223,"targetDuration":225,"studyType":22,"phases":4,"briefSummary":226,"conditions":227,"keywords":240,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":4},"100630769","development-and-multicenter-validation-of-an-ai-based-remote-photoplethysmography-rppg-facial-scan-for-multimodal-health-assessment-100630769","NCT07491978","Development and Multicenter Validation of an AI-Based Remote Photoplethysmography (rPPG) Facial Scan for Multimodal Health Assessment","Development and Multicenter Validation of an AI-Based Remote Photoplethysmography (rPPG) Facial Scan for Multimodal Health Assessment: Agreement With Clinical, Laboratory, and Psychological Parameters in an Urban Population","Inclusion Criteria:\n\n1. Adults aged ≥18 years.\n2. Able and willing to provide written informed consent.\n3. Able to comply with study procedures, including face scan, physical examination, blood sampling, and questionnaire completion.\n4. Clinically stable at the time of assessment.\n\nExclusion Criteria:\n\n1. Facial conditions affecting the region of interest (ROI), such as injury, deformity, or impaired circulation, that may interfere with rPPG signal acquisition.\n2. Presence of facial tattoos or coverings that obstruct optical signal detection.\n3. Inability to remain still or comply with measurement procedures during data acquisition.\n4. Severe medical conditions that preclude safe participation, as judged by the investigator.\n5. Incomplete data or withdrawal of consent during the study.\n\n   \\-",{"count":224,"type":21},1000,"1 Day","The goal of this observational study is to learn if a non-contact facial scan using artificial intelligence (AI) can be used to check health status in adults living in urban areas such as Jakarta. The facial scan uses a method called remote photoplethysmography (rPPG), which measures small changes in blood flow from the face using a camera.\n\nThe main questions this study aims to answer are:\n\n1. How close are the results from the facial scan to standard medical measurements, such as heart rate, breathing rate, blood pressure, and oxygen levels?\n2. Can the facial scan estimate other health indicators, such as blood sugar, lipid profile, HbA1c, and hemoglobin levels?\n3. Is there a relationship between the facial scan results and mental health, such as stress, anxiety, and depression?\n\nParticipants will take part in several simple and mostly non-invasive procedures:\n\n1. Answer questionnaires about their mental health and daily habits\n2. Have basic health checks, such as blood pressure, heart rate, and body measurements\n3. Provide a blood sample for laboratory testing\n4. Complete a facial scan using a camera for about 1 to 3 minutes\n\nResearchers will compare the results from the facial scan with standard clinical and laboratory tests to see how well the technology works.\n\nThis study may help develop a simple and accessible screening tool that can be used for early detection of health risks. It may also support the use of digital health and telemedicine in community and clinical settings.",[228,229,230,231,232,233,234,235,236,25,237,238,239],"Metabolic Syndrome","Hypertension","Diabetes (DM)","Tachycardia","ASCVD","Depression Disorder","Anxiety","Stress (Psychology)","Obesity & Overweight","Cardiometabolic Health Indicators","Sleep","Wellness",[241,242,243,244,245,246,247,248,249,250],"remote photoplethysmography","rPPG","artificial intelligence","digital biomarker","telemedicine","vital signs","cardiometabolic risk","machine learning","facial scan","screening tool","2026-04-15",{"date":253,"type":38},"2026-04-20",{"date":255,"type":21},"2026-04-24",{"date":257,"type":21},"2027-03-30",{"name":259,"class":90},"Tarumanagara University",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":99,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":103,"phases":269,"briefSummary":270,"conditions":271,"keywords":275,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":46},"100466406","breaking-up-prolonged-sedentary-behavior-to-improve-cardiometabolic-health-100466406","NCT05353322","Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health","Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health: An Adaptive Dose-Finding Study","Inclusion Criteria:\n\n* 18 years of age or older\n* Ability to read, write and speak English or Spanish\n* Limited or no chronic medical conditions \\[examples include but not limited to: CVD, diabetes, chronic obstructive pulmonary disease (COPD), HIV\u002FAIDS; participants with high blood pressure\u002Fhypertension and\u002For high cholesterol\u002Fhyperlipidemia may be included if they are currently prescribed and taking medication for these conditions\\]\n* Do not take medication (over-the-counter or herbal) to control glucose (such as a diabetes control medication)\n* Not currently pregnant\n* Do not currently smoke cigarettes\n* No pre-existing musculoskeletal conditions (including but not limited to osteoarthritis, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis) that would prevent participation in intermittent physical activity\n* No allergies to common food allergens including wheat, eggs, milk or other dairy, gluten, fructose, peanuts or other nuts\n* No dietary restrictions such as vegan, gluten free, halal\n\nExclusion Criteria:\n\n• Unable to provide consent",{"count":268,"type":21},324,[105],"The purpose of this Phase 1 research study is to answer two questions: (1) How frequent should periods of prolonged sedentary time be interrupted? and (2) What is the appropriate duration or length of time of these breaks in sedentary time? To address these questions, this project will conduct a state-of-the-art adaptive dose finding study under controlled laboratory conditions to determine the minimally effective dose (the smallest dose) that yields cardiometabolic benefit for two separate sedentary break elements (frequency and duration). Study findings will ultimately determine how often and for how long people should break up periods of prolonged sedentary time to transiently improve established cardiovascular risk factors; key foundational information critical to the success of future long-term trials and ultimately public health guidelines.\n\nPrimary Aim: To determine the minimally effective dose combination(s) of frequency and duration needed to provide cardiometabolic benefit during an 8-hour experimentation period. Specifically, the study will determine:\n\n1a. For each fixed duration, the minimum sedentary break frequency (e.g., every 30 min, 60 min, 120 min) that demonstrates a reduction in systolic BP, diastolic BP, or glucose compared with a sedentary control condition.\n\n1b. For each fixed frequency, the minimum sedentary break duration (e.g., activity breaks of 1 min, 5 min, 10 min) that demonstrates a reduction in systolic BP, diastolic BP, or glucose compared with a sedentary control.\n\nSecondary Aim: It is also critical to public health strategy to assess the acceptability\u002Ffeasibility of various sedentary break doses as too high a dose will yield poor uptake. To address this need, the maximally tolerated dose (the highest dose that does not cause undue physical\u002Fpsychological distress) for frequency and duration of sedentary breaks will also be determined via assessment of 4 constructs: physical exhaustion\u002Ffatigue, affect (e.g., mood, emotion), tolerability (e.g., completion of dose protocol), and safety (e.g., hypoglycemia). Maximally tolerated dose will be defined as the highest dose where \\\u003C20% of participants exhibit an adverse outcome.",[272,25,273,274],"Sedentary Behavior","Blood Pressure","Glucose",[272,75,273,274,276,277],"Insulin","Dose-finding","2026-04-06",{"date":280,"type":38},"2026-04-09",{"date":282,"type":38},"2022-06-30",{"date":284,"type":21},"2028-03-31",{"name":286,"class":90},"Columbia University",{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":294,"enrollmentInfo":295,"targetDuration":4,"studyType":103,"phases":297,"briefSummary":298,"conditions":299,"keywords":303,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":310,"completionDateStruct":311,"leadSponsor":313,"locationsCount":215},"100623725","impact-of-a-probiotic-supplementation-with-lifestyle-modification-on-liver-steatosis-fibrosis-and-metabolic-health-in-patients-with-metabolic-dysfunction-associated-steatotic-liver-disease-masld-100623725","NCT07400367","Impact of a Probiotic Supplementation With Lifestyle Modification on Liver Steatosis, Fibrosis, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","Impact of a Multi-strain Probiotic Supplementation With Lifestyle Modification on Liver Steatosis, Fibrosis, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","Inclusion Criteria:\n\n* ALT ≥ 60 U\u002FL\n* Liver steatosis identified by ultrasound\n* Meet at least one cardiometabolic criteria:\n\n  1. BMI ≥ 25 kg\u002Fm2 (Asian ≥23)\n  2. Waist circumference: \\> 94cm (M) 80cm(F)\n  3. Fasting blood glucose ≥ 100 mg\u002FdL\n  4. HbA1c ≥ 5.7\n  5. Receiving treatment of diabetes\n  6. Receiving treatment of Hypertension\n  7. Average home blood pressure: ≥ 130\u002F85 mmHg\n  8. TG ≥ 150 mg\u002FdL\n  9. HDL ≤ 40 mg\u002FdL\n  10. Receiving treatment of dyslipidemia\n\nExclusion Criteria:\n\n* HBsAg(+)\n* Anti-HCV (+)\n* Cirrhosis\n* Excessive alcohol intake ( Male over 210g\u002Fwk; Female over 140mg\u002Fwk)\n* Could not rule out Autoimmune hepatitis (ANA, or AMA or ASMA (+))\n* Could not rule out drug related hepatitis\n* Receiving drug that might induce liver steatosis:\n* Glucocorticoids\n* Amiodarone\n* Tamoxifen\n* Methotrexate\n* Valproate\n* Tetracycline\n* Chemotherapeutic agents\n* Receiving immune modulators or biologics\n* Receiving antibiotics within 1 month\n* Receiving any cancer treatment\n* Have diagnosis of \"Catastrophic Illness\" defined by Health Administration of Taiwan\n* eGFR\\\u003C60\n* Pregnancy\n* Currently enrolled in other dietary or pharmacology clinical trial","80 Years",{"count":296,"type":21},80,[105],"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the new clinical term introduced in 2023 to redefine what was formerly known as Non-Alcoholic Fatty Liver Disease (NAFLD). It is defined as fatty liver confirmed by imaging or biopsy, accompanied by at least one cardiometabolic risk factor (e.g., hyperglycemia, dyslipidemia, hypertension, or obesity). Its pathological progression ranges from simple steatosis to steatohepatitis, primarily driven by excessive energy intake, hepatic lipid accumulation, and insulin resistance.\n\nMASLD is currently the most prevalent chronic liver disease globally, with a prevalence rate of approximately 30-40%. However, there is no satisfactory pharmacological treatment, leaving lifestyle modification as the primary therapeutic approach. Many patients struggle to effectively adjust their habits, leading to persistent hepatic inflammation and damage, which may eventually progress to end-stage diseases such as cirrhosis and hepatocellular carcinoma. In many developed countries, MASLD has become the leading indication for liver transplantation, imposing a heavy burden on healthcare systems.\n\nGut dysbiosis is closely linked to MASLD. An imbalance in the gut microbiota disrupts the gut-liver axis, leading to impaired intestinal mucosal barrier function. This allows bacterial components to enter the circulation, further triggering hepatic inflammation and abnormal lipid metabolism. Consequently, modulating the gut microbiota is considered a potential therapeutic strategy.\n\nOver the past decade, probiotics, prebiotics, and synbiotics have been extensively studied as non-pharmacological treatments for NAFLD. Multiple studies indicate that these products can reduce liver enzymes (AST, ALT), insulin resistance (HOMA-IR), and inflammatory markers (hs-CRP, TNF-α). The most effective combinations typically involve Lactobacillus, Bifidobacterium, and Streptococcus, with a recommended duration of approximately 12 weeks. However, the impact of these products on liver fibrosis, hepatic fat accumulation, and cardiometabolic risk factors remains inconclusive.\n\nThe probiotic product to be tested consists of Lactobacillus salivarius AP-32, Lactobacillus rhamnosus bv-77, Bifidobacterium animalis CP-9, and Lactobacillus reuteri GL-104. This formulation complies with food safety regulations. In clinical studies, it had been proven as an effective adjuvant method that increased beneficial gut bacteria such as Akkermansia muciniphila and improved the control of blood glucose, lipids, and inflammatory markers.\n\nStudy Objectives\n\nThis study aims to investigate the efficacy of this probiotic product as an adjuvant therapy alongside lifestyle modifications in adult patients with MASLD. We will evaluate its impact on:\n\n1. The degree of liver fibrosis and steatosis\n2. Cardiometabolic risk factors (BMI, waist circumference, blood lipids, and blood glucose).\n3. Inflammatory markers.\n4. Gut microbiota composition.",[300,301,302,73,25],"Liver Elastography","Liver Steatosis","Liver Function Test",[304,305,306,307],"MASLD","Probiotics","Liver fibrosis","Liver steatosis","2026-04-03",{"date":278,"type":38},{"date":186,"type":38},{"date":312,"type":21},"2027-08",{"name":314,"class":90},"Fu Jen Catholic University Hospital",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":103,"phases":324,"briefSummary":325,"conditions":326,"keywords":329,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":46},"100632398","phase-4-low-dose-semaglutide-for-weight-loss-in-obese-non-diabetic-pakistani-adults-100632398","NCT07513168","Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults","Efficacy and Safety of Low-Dose Semaglutide for Weight Loss and Cardiometabolic Improvement in Obese Pakistani Adults Without Type 2 Diabetes: A Single-Arm Open-Label Single-Center Trial","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Body mass index (BMI ≥ 27.5 kg\u002Fm²) according to WHO Asian cut-offs.\n* No diagnosis of type 2 diabetes mellitus, confirmed by:\n\nFasting blood glucose \\\u003C 126 mg\u002FdL, and HbA1c \\\u003C 6.5% within three months prior to enrollment.\n\n* Willingness and ability to provide written informed consent.\n* Willingness to comply with study procedures, including weekly injections and lifestyle counseling.\n\nExclusion Criteria:\n\n* History of pancreatitis.\n* History or presence of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).\n* Pregnant or lactating women.\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or hepatic impairment (ALT or AST \\> 3× upper limit of normal).\n* Current use of other anti-obesity medications.\n* Known hypersensitivity to semaglutide or any component of the formulation.\n* Any condition that, in the investigator's opinion, would interfere with participation, adherence, or safety in the study.",{"count":323,"type":21},60,[169],"This prospective, open-label, single-arm, single-center interventional pilot trial aims to evaluate the efficacy and safety of low-dose semaglutide for weight loss and cardiometabolic improvement in obese Pakistani adults without type 2 diabetes mellitus. The study will be conducted at the Asian Institute of Medical Sciences (AIMS), Hyderabad, Sindh, Pakistan. A total of 60 obese adults aged 18 years or older with a body mass index (BMI) of 27.5 kg\u002Fm² or greater according to World Health Organization Asian cutoffs and without type 2 diabetes mellitus (fasting blood glucose \\\u003C126 mg\u002FdL and HbA1c \\\u003C6.5%) will be enrolled. Eligible participants will receive once-weekly subcutaneous semaglutide following a standard dose titration schedule of 0.25 mg weekly for four weeks, 0.5 mg weekly for four weeks, and 1.0 mg weekly for the remaining 16 weeks, for a total treatment duration of 24 weeks. All participants will receive standardized lifestyle counseling, including a hypocaloric diet with a 500-750 kcal\u002Fday deficit and at least 150 minutes per week of moderate-intensity physical activity. The primary outcome is the percentage change in body weight from baseline to 24 weeks. Secondary outcomes include changes in body mass index, waist circumference, systolic and diastolic blood pressure, lipid profile (total cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides), liver enzymes (alanine aminotransferase and aspartate aminotransferase), and quality of life. Safety will be assessed through continuous monitoring of adverse events and adverse drug reactions with causality assessment using the Naranjo Adverse Drug Reaction Probability Scale. Clinical and laboratory assessments will be conducted at baseline, 12 weeks, and 24 weeks. Data will be analyzed using descriptive and inferential statistics, including paired t-tests or non-parametric equivalents and repeated measures analysis, with a significance level of p \\\u003C 0.05. The study will be conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki, with approval from the AIMS Institutional Review Board and written informed consent obtained from all participants. The trial aims to generate locally relevant clinical evidence on the effectiveness and safety of low-dose semaglutide for obesity management in non-diabetic Pakistani adults.",[327,328,25],"Obesity","Weight Reduction",[330,327,331,332,333,334,335,336,337,338],"Semaglutide","Weight loss","GLP-1 Receptor Agonist","Body Mass Index","Open label trial","Cardiometabolic risk","Single Arm Study","Pakistan","Obesity Pharmacotherapy",{"date":278,"type":38},{"date":341,"type":38},"2025-08-01",{"date":343,"type":21},"2026-12-01",{"name":345,"class":90},"Asian Institute Of Medical Sciences",{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":11,"sex":16,"minAge":353,"maxAge":165,"enrollmentInfo":354,"targetDuration":4,"studyType":103,"phases":355,"briefSummary":356,"conditions":357,"keywords":360,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":46},"100626560","effect-of-ginger-capsules-on-inflammation-oxidative-stress-and-endothelial-function-100626560","NCT07437222","Effect of Ginger Capsules on Inflammation, Oxidative Stress, and Endothelial Function","Study of the Effect of Ginger Capsules on Markers of Inflammation, Oxidative Stress, and Endothelial Damage","Inclusion Criteria:\n\n* Male and female participants.\n* Age between 23 and 65 years.\n* Body mass index (BMI) \\> 27.5 kg\u002Fm².\n* Absence of diagnosed chronic diseases.\n* Not receiving pharmacological treatment or dietary supplementation on a regular basis.\n* Ability to understand the study procedures and willingness to comply with study requirements.\n\nExclusion Criteria:\n\n* Presence of acute or chronic diseases not specified in the inclusion criteria.\n* Ongoing chronic pharmacological treatment or active use of dietary supplements.\n* Major surgery within the previous three months.\n* Current smokers or recent former smokers (less than six months since cessation).\n* History of clinically relevant food allergies or eating disorders.\n* Concurrent participation in another clinical trial or research study.\n* Pregnancy or breastfeeding.\n* Following an active weight-loss diet.\n* Investigator's judgment of unsuitability for study participation.","23 Years",{"count":20,"type":21},[105],"Randomized, double-blind, parallel, placebo-controlled clinical trial designed and conducted to evaluate the effect of daily consumption of ginger, on parameters related to inflammation, oxidative stress, and endothelial damage in adults with excess adiposity.",[358,359,25],"Inflammation Biomarkers","Oxidative Stress",[358,359,361,362],"Randomized Controlled Trial","Ginger","2026-03-05",{"date":365,"type":38},"2026-03-09",{"date":367,"type":38},"2026-03-02",{"date":369,"type":21},"2026-06",{"name":371,"class":90},"Ana Mª Garcia Munoz",{"id":373,"slug":374,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":11,"sex":16,"minAge":353,"maxAge":165,"enrollmentInfo":378,"targetDuration":4,"studyType":103,"phases":379,"briefSummary":356,"conditions":380,"keywords":381,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":388,"locationsCount":46},"100626312","effect-of-a-ginger-based-beverage-on-inflammation-oxidative-stress-and-endothelial-function-100626312","NCT07433998","Effect of a Ginger-Based Beverage on Inflammation, Oxidative Stress, and Endothelial Function","Study of the Effect of a Ginger-based Functional Beverage on Markers of Inflammation, Oxidative Stress, and Endothelial Damage.",{"count":20,"type":21},[105],[358,359,25],[382,359,361,362],"inflammation Biomarkers",{"date":384,"type":38},"2026-03-04",{"date":386,"type":21},"2026-03",{"date":369,"type":21},{"name":389,"class":90},"Javier Marhuenda",{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":396,"eligibilityCriteria":397,"healthyVolunteers":99,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":103,"phases":399,"briefSummary":400,"conditions":401,"keywords":402,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":46},"100620899","pilot-test-of-five-weight-neutral-interventions-to-improve-health-among-adults-of-higher-body-weight-100620899","NCT07363616","Pilot Test of Five Weight Neutral Interventions to Improve Health Among Adults of Higher Body Weight","Optimizing a Weight Neutral Intervention to Improve Health Among Adults of Higher Body Weight: A MOST Preparation Phase Study","NEW PATH","Inclusion Criteria:\n\n* 18 years and older\n* BMI between 25-40 (if BMI is between 25-30 then additional cardiometabolic risk factor must be present including hypertension, high cholesterol, prediabetes or type 2 diabetes)\n\nExclusion Criteria:\n\n* current participation in a formal weight loss program\n* current use of weight loss medication\n* history of bariatric surgery\n* physical condition that would limit the ability to engage in moderate intensity physical activity\n* current pregnancy\n* recent weight loss of 5% body weight\n* condition that may interfere with ability to complete the study procedures",{"count":20,"type":21},[105],"The purpose of this research study is to pilot test five different, group based and remotely delivered programs designed to support healthy eating and regular physical activity. Each group will contain information and support for healthy eating and physical activity. Groups may also include support to 1) eat with more awareness of hunger and fullness, 2) improve how people think and feel about their bodies, and\u002For 3) identify ways to be physically active that are more enjoyable. Each group will include a unique combination of these components and the goal is to assess overall satisfaction and engagement with each of the programs.",[236,25],[403,75,404,405,406,407,408,327,409,410,411,412,413],"Mediterannean diet","Weight Neutral","Lifestyle intervention","Mindful eating","Mindfulness-based Eating Awareness Training","Body Image","Overweight","Cardiometabolic health","Multiphase Optimization STrategy (MOST)","MOST Preparation Phase","Body appreciation","2026-01-22",{"date":416,"type":38},"2026-01-23",{"date":418,"type":38},"2025-12-31",{"date":420,"type":21},"2026-11-15",{"name":422,"class":90},"The Miriam Hospital",{"id":424,"slug":425,"hasResults":11,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":429,"eligibilityCriteria":430,"healthyVolunteers":99,"sex":128,"minAge":4,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":103,"phases":433,"briefSummary":434,"conditions":435,"keywords":437,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":446,"locationsCount":46},"100564761","alternative-physical-activity-strategies-for-breast-cancer-survivors-100564761","NCT06633380","Alternative Physical Activity Strategies for Breast Cancer Survivors","Alternative Physical Activity Strategies for Breast and Prostate Cancer Survivors","PACE","Inclusion Criteria:\n\n* Postmenopausal biological females diagnosed with stage I, II, or III breast cancer and currently using aromatase inhibitors (AI) for at least 3 months prior to start of study participation\n* All participants must meet the following criteria:\n\n  * Body mass index equal to or greater than 25 kg\u002Fm\\^2.\n  * Self-report consuming three main meals daily.\n  * Self-report as being sedentary (i.e., less than 30 minutes\u002Fweek of moderate-to-vigorous aerobic physical activity and less than twice\u002Fweek muscle strengthening of major muscle groups in the last three months.\n\nExclusion Criteria:\n\n* If unable or unwilling to receive medical clearance by a physician after being screened for major signs or symptoms of cardiovascular diseases, diabetes, or renal disease and safety to initiate exercise.\n\n  * Major signs or symptoms of cardiovascular diseases, diabetes, or renal disease are taken from the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription 11th edition Table 2.1. They include pain or discomfort in the chest, neck, jaw, arms with rest or exercise, shortness of breath at rest or with mild exertion, dizziness or syncope, ankle edema, palpitations or tachycardia, intermittent claudication, known heart murmur, and unusual fatigue with usual activities.\n  * Safety to initiate exercise will be screened using the Get Active Questionnaire, which is the Canadian Society of Exercise Physiology's endorsed evidence-based pre-screening tool.\n* Using drugs for diabetes management (e.g., exogenous insulin, Ozempic, metformin, etc.) or actively losing weight (i.e., \\>5 kg weight loss in past 3 months) from drugs or other reasons\n* Report any injury or other reason for not feeling capable of completing a 30 minute continuous walk or muscle strengthening exercise\n* Unable to access an Ontario Lifelabs location for an overnight fasted blood draw\n* Do not have a smartphone compatible with the applications required to collect data.\n* Cannot read and understand the consent form or communicate in English.",{"count":432,"type":21},24,[105],"The primary aim of this study is to compare the acute glycemic effects of two novel, alternative physical activity (PA) strategies (dispersed post-meal PA, PA snacks) to a no PA condition and to exercise sessions representing the PA guidelines (standard 30-minute walking bout performed under fasting and under postprandial conditions and a standard 30-minute resistance training session) among sedentary breast cancer survivors who are currently receiving hormone therapies and age- and BMI-matched postmenopausal women without a history of cancer. The secondary aim is to determine whether the alternative PA strategies are acceptable and feasible in the free-living setting. An exploratory aim is to determine whether the outcomes differ between women with and without a history of breast cancer and use of aromatase inhibitors.\n\nThe investigators hypothesize that:\n\n1. Dispersed PA and PA snacks will result in greater reductions in 24-hour glucose and postprandial glucose compared to the no-PA baseline and similar reductions to a standard 30-minute bouts of walking;\n2. The alternative PA strategies will be more feasible and have greater acceptability by cancer survivors compared to the standard 30-minute bout of walking or resistance training; and\n3. The different PA strategies will have similar effects on glycemic outcomes for both breast cancer survivors and cancer-free controls. The resistance exercise session is an exploratory trial as the effects of it on acute glycemic control are understudied.",[436,73,25],"Breast Cancer",[75,438,439],"Hormone Therapy","Glycemic Control","2025-11-24",{"date":442,"type":38},"2025-12-02",{"date":444,"type":38},"2024-10-22",{"date":52,"type":21},{"name":447,"class":90},"University of Toronto",{"id":449,"slug":450,"hasResults":11,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":11,"sex":16,"minAge":455,"maxAge":456,"enrollmentInfo":457,"targetDuration":4,"studyType":103,"phases":459,"briefSummary":460,"conditions":461,"keywords":462,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":470,"locationsCount":215},"100597066","effect-of-vitamin-d-on-cardiovascular-metabolic-risk-in-overweightobesity-adolescents-in-china-100597066","NCT07053657","Effect of Vitamin D on Cardiovascular Metabolic Risk in Overweight\u002FObesity Adolescents in China","The Improvement Effect of Vitamin D on the Cardiovascular Health of Overweight\u002FObesity Adolescents in China","Inclusion Criteria:\n\n1. Students whose caregivers signed informed consents;\n2. Students with serum 25(OH)D concentration of 12-20 ng\u002FmL;\n3. Students with overweight or obesity.\n\nExclusion Criteria:\n\n1. Students with any disease that affects vitamin D metabolism (e.g., functional\u002Forganic brain disease, severe infectious disease, chronic gastrointestinal disease, hepatic or renal insufficiency, etc.);\n2. Students with known chronic disease (e.g., cardiovascular disease); use of vitamin D supplements in the past 3 months;\n3. Students with allergies to vitamin D or soybean oil ingredients.","10 Years","16 Years",{"count":458,"type":21},130,[105],"The goal of this randomized controlled clinical trial is to investigate the effects of vitamin D3 supplementation on cardiometabolic risk in Chinese adolescents with overweight\u002Fobesity and vitamin D deficiency. The main question it aims to answer whether vitamin D3 supplementation can improve cardiovascular metabolic health.\n\nParticipants in the intervention group will receive vitamin D3. The control group will receive vitamin D placebo.\n\nResearchers will compare the change in cardiometabolic risk from baseline to post-intervention at 12 weeks between the intervention and control groups.",[25],[247,463],"vitamin D","2025-11-14",{"date":466,"type":38},"2025-11-17",{"date":468,"type":38},"2025-09-15",{"date":418,"type":21},{"name":471,"class":90},"Anhui Medical University",{"id":473,"slug":474,"hasResults":11,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":99,"sex":16,"minAge":479,"maxAge":294,"enrollmentInfo":480,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":482,"conditions":483,"keywords":488,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":46},"100575657","associations-between-dietary-intake-and-cardiometabolic-and-gut-microbiota-outcomes-100575657","NCT06775132","Associations Between Dietary Intake and Cardiometabolic and Gut Microbiota Outcomes","Associations Between Dietary Intake and Cardiometabolic and Gut Microbiota Outcomes in Singapore Adults","Inclusion Criteria:\n\n1. Able to give informed consent\n2. Adults 21-80 years old\n3. English-literate\n4. Have venous access sufficient to allow for blood sampling as per the protocol\n5. No drastic change of diet for the past 1 year\n6. If taking medication, has been consistently taking antihypertensive\u002Fcholesterol-lowering\u002Ftype-2 diabetic medication for more than 5 years prior to starting the study.\n\nExclusion Criteria:\n\n1. Taking dietary supplements and fermented foods, which may impact the gut microbiota (e.g. antibiotics, prebiotics, probiotics, yogurt, kimchi) 2 months before starting the 1st study visit only.\n2. Taking dietary supplements or medications, which may impact sleep outcomes (e.g. Nutritional Shakes (e.g. Ensure), tryptophan, 5-hydroxytryptophan or melatonin supplementations) 1 month before starting the study.\n3. Taking dietary supplements which may impact the eye outcomes (e.g. Vitamin A, vitamin A-containing multivitamin) 2 months before starting the study.","21 Years",{"count":481,"type":21},240,"This cross-sectional study aims to investigate the associations between dietary intake, cardiometabolic health markers, and gut microbiota composition in Singapore adults.",[25,484,485,486,487],"Gut -Microbiota","Skin Condition","Cognitive Ability, General","Sleep Quality",[489,490,491,492,493],"Endothelial progenitor cells","Gut microbiota","Cardiovascular diseases risk factors","MoCA","Advanced glycation end products",{"date":495,"type":38},"2025-05-21",{"date":497,"type":38},"2025-02-03",{"date":499,"type":21},"2025-12-30",{"name":501,"class":90},"National University of Singapore",{"id":503,"slug":504,"hasResults":11,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":508,"eligibilityCriteria":509,"healthyVolunteers":99,"sex":128,"minAge":479,"maxAge":129,"enrollmentInfo":510,"targetDuration":4,"studyType":103,"phases":512,"briefSummary":513,"conditions":514,"keywords":517,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":526,"locationsCount":46},"100579564","asian-mediterranean-diet-and-womens-health-100579564","NCT06825936","Asian-Mediterranean Diet and Women's Health","Asian-Mediterranean Diet and Women's Health: A Randomized Controlled Trial (A+ MEAL Study)","A+ MEAL","Inclusion Criteria:\n\nSubjects must meet all of the inclusion criteria for participation:\n\n1. Females aged 21-50 years\n2. Chinese ethnicity\n3. Singapore citizens, permanent residents, or long-term pass holders\n4. Is able to complete questionnaires in English\n5. BMI ≥ 23.0 kg\u002Fm2 but \\\u003C 37.5 kg\u002Fm2\n6. Not planning to conceive in the next 12 months from enrolment (you will be asked to withdraw once you conceive during the study period)\n7. Not planning to leave Singapore for more than 2 consecutive calendar weeks (10 working days) in the next six months from enrolment\n8. Not currently pregnant or breastfeeding\n9. Not currently smoking\n10. Without history of major chronic diseases (e.g., cancer, diabetes, cardiovascular diseases, chronic kidney disease), major infectious diseases (e.g. hepatitis B, HIV), severe gastrointestinal disorders (e.g. colitis or inflammation of the bowel, celiac disease, chronic gastritis) and major medical procedures\u002Fsurgeries related to these conditions\n11. Without major mental health condition\n12. Without known food allergies, especially to nuts and seafood.\n13. Not on any special diets or having dietary restrictions (e.g. vegetarians, vegans, ketogenic, Kosher diet)\n14. Not currently and will not be enrolled in another interventional study or studies that may affect weight, cardiometabolic health, gut, or brain health in the next six months from enrolment\n\nExclusion Criteria:\n\nSubjects not meeting any of the above inclusion criteria will be excluded from participation.\n\nAdditional Exclusion Criteria for MRI procedure only:\n\ni. Shoulder width ≥60cm ii. Has any medical implants or foreign bodies, particularly related to heart, brain, or eye implants, including but not limited to pacemakers, artificial heart valves, implantable cardioverter defibrillators, ventricular assist devices, brain stimulation devices, intrauterine devices, and breast biopsies (if any implant or tissue marker has been placed) iii. History of head injury or trauma with loss of consciousness iv. Metallic dental braces or dental implants v. Having claustrophobia vi. Drinks more than 30 units of alcohol per week (1 unit = 25mL 40% spirit, 1 can of beer = 2 units, 1 standard glass of wine = 2 units)",{"count":511,"type":21},300,[105],"Given the escalating high burdens of overeight and obesity, and related commobidies in Asia, Asian women with overweight\u002Fobesity is an important group for targeted intervention in promoting health and wellbeing. A study focused on Asian women at reproductive or early post-menopausal age can inform effective strategies for promoting healthy diet and lifetyle and for optimizing health not only among these women but also for their children and partners.\n\nThe Mediterranean diet has beneficial effects on cardiometabolic and reproductive health. So far, evidence on the Mediterranean diet and its health benefits mostly come from Western populations. Studies evaluating health effects of Mediterranean diet in Asian population are scant.\n\nThis study aims to investigate the beneficial effects of a healthy, Mediterranean-inspired localized diet (i.e., Asian-Mediterranean diet) on women's health, such as cardiometabolic health with potential mechanisms through modulating gut and brain health.",[25,515,516],"Cardiometabolic Conditions","Women Health",[410,518,519,206],"Mediterranean diet","Women health","2025-03-10",{"date":522,"type":38},"2025-03-12",{"date":524,"type":38},"2025-02-10",{"date":154,"type":21},{"name":527,"class":90},"Global Centre for Asian Women's Health"]